RAGE blockade and hepatic microcirculation in experimental endotoxaemic liver failure

British Journal of Surgery

Volumn 100, Issue 9, 2013, Pages 1229-1239

  Kuhla, A ^a   Norden, J ^a   Abshagen, K ^a   Menger, M D ^b   Vollmar, B ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCOSYLATION END PRODUCT RECEPTOR; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; ANTIBODY; GALACTOSAMINE; IMMUNOGLOBULIN RECEPTOR; LIPOPOLYSACCHARIDE;

ANIMAL; ARTICLE; C57BL MOUSE; DRUG ANTAGONISM; ENDOTOXEMIA; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOLOGY; INNATE IMMUNITY; KNOCKOUT MOUSE; LIVER; LIVER CIRCULATION; LIVER FAILURE; MALE; MICROCIRCULATION; MOUSE; PHYSIOLOGY; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; UPREGULATION; VASCULARIZATION;

ANIMALS; ANTIBODIES; ENDOTOXEMIA; FLUORESCENT ANTIBODY TECHNIQUE; GALACTOSAMINE; IMMUNITY, INNATE; LIPOPOLYSACCHARIDES; LIVER; LIVER CIRCULATION; LIVER FAILURE; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROCIRCULATION; RECEPTORS, IMMUNOLOGIC; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; UP-REGULATION;

EID: 84880135909     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.9188     Document Type: Article

References (24)

1. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101: 1644-1655.
2. Dombrovskiy VY, Martin AA, Sunderram J, Paz HL,. Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003. Crit Care Med 2007; 35: 1244-1250.
3. McDonald B, Kubes P,. Neutrophils and intravascular immunity in the liver during infection and sterile inflammation. Toxicol Pathol 2012; 40: 157-165.
4. Vollmar B, Menger MD,. The hepatic microcirculation: mechanistic contributions and therapeutic targets in liver injury and repair. Physiol Rev 2009; 89: 1269-1339.
5. Kortgen A, Paxian M, Werth M, Recknagel P, Rauchfuss F, Lupp A, et al. Prospective assessment of hepatic function and mechanisms of dysfunction in the critically ill. Shock 2009; 32: 358-365.
6. Akira S, Uematsu S, Takeuchi O,. Pathogen recognition and innate immunity. Cell 2006; 124: 783-801.
7. Jack RS, Fan X, Bernheiden M, Rune G, Ehlers M, Weber A, et al. Lipopolysaccharide-binding protein is required to combat a murine gram-negative bacterial infection. Nature 1997; 389: 742-745.
8. Arancibia SA, Beltrán CJ, Aguirre IM, Silva P, Peralta AL, Malinarich F, et al. Toll-like receptors are key participants in innate immune responses. Biol Res 2007; 40: 97-112.
9. van Zoelen MA, Achouiti A, van der Poll T,. The role of receptor for advanced glycation endproducts (RAGE) in infection. Crit Care 2011; 15: 208.
10. Schmidt AM, Yan SD, Yan SF, Stern DM,. The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta 2000; 1498: 99-111.
11. Bierhaus A, Humpert PM, Morcos M, Wendt T, Chavakis T, Arnold B, et al. Understanding RAGE, the receptor for advanced glycation end products. J Mol Med (Berl) 2005; 83: 876-886.
12. Zhang H, Tasaka S, Shiraishi Y, Fukunaga K, Yamada W, Seki H, et al. Role of soluble receptor for advanced glycation end products on endotoxin-induced lung injury. Am J Respir Crit Care Med 2008; 178: 356-362.
13. Kuhla A, Hettwer C, Menger MD, Vollmar B,. Oxidative stress-associated rise of hepatic protein glycation increases inflammatory liver injury in uncoupling protein-2 deficient mice. Lab Invest 2010; 90: 1189-1198.
14. Frommhold D, Kamphues A, Hepper I, Pruenster M, Lukic IK, Socher I, et al. RAGE and ICAM-1 cooperate in mediating leukocyte recruitment during acute inflammation in vivo. Blood 2010; 116: 841-849.
15. Eipel C, Bordel R, Nickels RM, Menger MD, Vollmar B,. Impact of leukocytes and platelets in mediating hepatocyte apoptosis in a rat model of systemic endotoxemia. Am J Physiol Gastrointest Liver Physiol 2004; 286: G769-G776.
16. Cataldegirmen G, Zeng S, Feirt N, Ippagunta N, Dun H, Qu W, et al. RAGE limits regeneration after massive liver injury by coordinated suppression of TNF-alpha and NF-kappaB. J Exp Med 2005; 201: 473-484.
17. Eipel C, Kidess E, Abshagen K, Leminh K, Menger MD, Burkhardt H, et al. Antileukoproteinase protects against hepatic inflammation, but not apoptosis in the response of d -galactosamine-sensitized mice to lipopolysaccharide. Br J Pharmacol 2007; 151: 406-413.
18. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 2009; 55: 611-622.
19. Liliensiek B, Weigand MA, Bierhaus A, Nicklas W, Kasper M, Hofer S, et al. Receptor for advanced glycation end products (RAGE) regulates sepsis but not the adaptive immune response. J Clin Invest 2004; 113: 1641-1650.
20. Zeng S, Feirt N, Goldstein M, Guarrera J, Ippagunta N, Ekong U, et al. Blockade of receptor for advanced glycation end product (RAGE) attenuates ischemia and reperfusion injury to the liver in mice. Hepatology 2004; 39: 422-432.
21. Basta G, Lazzerini G, Massaro M, Simoncini T, Tanganelli P, Fu C, et al. Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation 2002; 105: 816-822.
22. Medzhitov R, Preston-Hurlburt P, Kopp E, Stadlen A, Chen C, Ghosh S, et al. MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. Mol Cell 1998; 2: 253-258.
23. Lin L., RAGE on the Toll Road? Cell Mol Immunol 2006; 3: 351-358.
24. Yamamoto Y, Harashima A, Saito H, Tsuneyama K, Munesue S, Motoyoshi S, et al. Septic shock is associated with receptor for advanced glycation end products ligation of LPS. J Immunol 2011; 186: 3248-3257.